Ferrer and Treeway Enter Into Licence Agreement for the Development and Commercialisation of TW001/FNP122 for Amyotrophic Lateral Sclerosis

Ferrer, an international pharmaceutical company focused on pulmonary vascular and interstitial lung diseases and neurological disorders, and Treeway, a clinical-stage biotechnology company, have announced they have entered into a licence agreement for the development and commercialisation of an oral formulation of edaravone (TW001/FNP122) for Amyotrophic Lateral Sclerosis (ALS) in certain territories, including Europe and some Asian countries. Under the terms of the licence agreement, Ferrer is responsible for advancing the development and commercialisation of the product and will make royalty payments to Treeway at certain milestones.

The deal leverages Ferrer’s strong capabilities and expertise in neurology to underscore both companies’ commitment to expanding global access to TW001/FNP122 for the treatment of ALS. 

Inez de Greef, CEO at Treeway comments: “Guided by patients, we have developed TW001/FNP122 through the early stages of development. We are therefore delighted that Ferrer has committed to advance our lead product to the required pivotal phase III trial and make it available for ALS patients in large parts of the world.”

Oscar Pérez, Ferrer’s Chief BD&L Officer, adds: “Driven by our purpose of bringing transformative products to patients the world over, we are pleased to enter the agreement with Treeway and look forward to patients benefiting from improved treatment options. TW001/FNP122 is the perfect fit for Ferrer’s strategy to bring new molecules to late-stage clinical development, registration and market entry in the field of neurological disorders and strengthen our pipeline for the coming years.”